PACBNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$1.84+0.11 (+6.36%)
Close on Oct 19, 2026
- Market cap
- $571.61M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
28.6%−12.7 pts over 5 years
Operating margin
-346.2%−213.8 pts over 5 years
Net margin
-341.5%−378.7 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +3.9% | +7.6% | +15.2% | +5.6% | |
| Gross profit | +22.8% | -2.3% | +7.0% | -1.5% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -94.0% | 15.1% | -213.5% | |
| Return on assets | -55.3% | 10.5% | -53.4% | |
| Current ratio | 3.23 | 9.24 | 5.15 | |
| Debt to equity | 0.19 | – | – | |
| Net debt to EBITDA | 0.08× | – | – | |
| Interest coverage | -22.0× | -391.0× | -79.6× | |
| Inventory turnover | 3.5× | 3.4× | 2.1× | |
| Capex to revenue | 9.0% | 1.3% | 1.7% | |
| Diluted shares | 89M | 175M | 300M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Pacific Biosciences Of California generated $950.83M from operations and spent $40.43M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$950.83M
Used
$40.43M
Capital expenditure$40.43M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-341.5%
×Asset turnover0.16×
×Equity multiplier3.99×
=Return on equity, FY2025-213.5%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -341.5% | 0.16× | 3.99× | -213.5% |
| FY2024 | -201.2% | 0.10× | 2.49× | -51.3% |
| FY2023 | -153.0% | 0.11× | 2.78× | -48.5% |
| FY2022 | -244.9% | 0.07× | 2.79× | -46.4% |
| FY2021 | -138.9% | 0.11× | 2.15× | -32.2% |
| FY2020 | 37.3% | 0.28× | 1.44× | 15.1% |
| FY2019 | -92.6% | 0.57× | 1.88× | -99.6% |
| FY2018 | -130.4% | 0.50× | 1.57× | -102.5% |
| FY2017 | -98.6% | 0.66× | 1.65× | -108.0% |
| FY2016 | -82.0% | 0.67× | 1.70× | -94.0% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$546.38M
- Cash generatingOperating cash flow above zero-$111.21M
- Return on assets improvedROA up on the prior year-17.7% → -43.3%
- Earnings backed by cashOperating cash flow above net income-$111.21M vs -$546.38M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose7.48 → 5.15
- No dilutionShare count did not rise288M → 300M
- Gross margin improvedGross margin up on the prior year24.21% → 28.61%
- More efficientAsset turnover rose0.09 → 0.13